Currently, the decision to treat BC patients by chemotherapy is currently driven by taking into account various clinicopathologic factors, such as patient age, disease stage, tumor grade, ER, and PR status, as well as the overexpression or amplification of HER2 (Adjuvant!Online and PREDICT tools) [30]. This evidence concerns the gene ESR1 and breast cancer.